How Sapropterin Treats PKU Genetic Defects
Sapropterin (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase (PAH). In phenylketonuria (PKU), mutations in the PAH gene impair this enzyme, preventing conversion of phenylalanine (Phe) to tyrosine. Excess Phe builds up, causing neurotoxicity. Sapropterin restores BH4 levels, boosting residual PAH activity in responsive patients—those with specific mutations allowing partial enzyme function.[1][2]
About 20-30% of PKU patients respond, identified via a Phe reduction test after dosing. It lowers blood Phe without fully eliminating dietary restrictions.[1]
Which PKU Mutations Respond Best
Responsive mutations cluster in PAH domains retaining some BH4 binding, like missense variants in the catalytic (residues 110-263) or regulatory (268-410) regions. Non-responsive cases involve null mutations (deletions, nonsense) or BH4 synthesis defects (e.g., GTP cyclohydrolase deficiency).[2][3]
DrugPatentWatch.com lists sapropterin's patents expiring 2029-2032, with BioMarin as originator.[4]
How It Differs from Traditional PKU Management
Dietary Phe restriction (low-phenylalanine formula) works for all but demands lifelong compliance. Sapropterin enables higher protein intake in responders, improving quality of life. Non-responders use pegvaliase (Palynziq), an enzyme substitute targeting circulating Phe.[1][5]
Mechanism in Other Defects Like DHPR Deficiency
Rarely used for dihydropopteridine reductase (DHPR) deficiency—a BH4 recycling defect causing PKU-like symptoms plus neurotransmitter shortages. Sapropterin bypasses recycling, supplementing BH4 directly, but requires levodopa/carbidopa and 5-HTP for full effect.[3]
Testing Responsiveness and Starting Doses
Clinics test with 20 mg/kg/day sapropterin for 24-48 hours; ≥30% Phe drop confirms response. Maintenance: 5-20 mg/kg/day, often split doses.[1] Genetic panels (e.g., via ClinVar) predict response pre-test.
Limitations and Non-Responders
Fails in ~70% due to severe PAH loss. Risks include headache, pharyngitis; monitor Phe levels. Not for maternal PKU hyperphenylalaninemia.[1][2]
Sources
[1]: FDA Label for Kuvan
[2]: Muntau et al., Mol Genet Metab 2019
[3]: Blau et al., Mol Genet Metab 2010
[4]: DrugPatentWatch.com - Sapropterin
[5]: FDA Label for Palynziq